,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['tnbc', 'bcsm']
dr. modi presents groundbreaking db-04 - #tdxd vs. chemo in #her2low #bcsm pfs - all: 5.1 mo chemo vs. 9.9 mo tdxd
-hr+: 5.4 vs. 10.1 mo os -all: 16.8 to 23.4 mo
-hr+: 17.5 to 23.9 mo tnbc:
-pfs 2.9 to 8.5 mo, -os 8.3 to 18.2 mo all significant! #asco22 
Med Onc, Director of Breast & GYN Research Program @ Sarah Cannon Research Institute #bcsm #gyncsm #WomenInMedicine USAF Wife, Mom to 2 girls, tweets are mine.